Atea Pharmaceuticals opened lower at $4.17, compared with its previous close of $4.22. In the last trading session, the stock traded between $4.09 and $4.29. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Atea Pharmaceuticals is now worth
$ 39.61
Resulting in a loss of
$ 60.39 (60.39%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-0.01 (-0.14%)
Day High
$4.29
Day Low
$4.09
Day Open
$4.17
Prev Close
$4.22
Volume
2,02,001
1W Return
-5.43%
1M Return
-16.47%
3M Return
-16.80%
6M Return
-22.11%
1Y Return
24.67%
Fundamentals
Market Cap ($ Mn)
338
PE Ratio
-
PB Ratio
2.11
PEG Ratio
-
ROE
-43.85%
ROCE
-49.32%
EPS (TTM)
$-0.40
Investment Returns
1 Week
-5.43%
1 Month
-16.47%
3 Months
-16.80%
6 Months
-22.11%
9 Months
-5.52%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
Atea Pharmaceuticals Q3FY26 Results: Cash $191.2M, New $200M Facility
Reported $191.2 million in cash and marketable securities as of September 30, 2026. Entered into a $200 million credit facility with Hercules Capital, drawing $65 million at closing. Phase 3 C-Beyond trial met primary endpoints with 94% SVR rate vs 95% for standard of care. Targeting NDA submission for bemnifosbuvir/ruzasvir by mid-2027 and U.S. launch in 2028.
3 days ago
13Aug
Atea Pharmaceuticals Q2 Results: Net loss narrows to $32.9M
Atea Pharmaceuticals reported a Q2 2026 net loss of $32.9 million, improving from $37.2 million YoY due to lower R&D costs. Cash reserves fell to $219.5 million. The company highlighted positive Phase 3 HCV trial results and advancing HEV development.
3mo ago
28Jul
Atea Pharma's HCV drug matches Gilead's Epclusa in pivotal trial
Atea Pharmaceuticals reported positive topline findings from its Phase 3 C-BEYOND trial, where its HCV therapy demonstrated statistical non-inferiority to Gilead Sciences' Epclusa. The study included 905 patients, with BEM/RZR achieving a 93.9% SVR rate overall and allowing for shorter treatment durations in non-cirrhotic patients.
3mo ago
14Jul
Atea Pharmaceuticals initiates Phase 1 trial for AT-587
Atea Pharmaceuticals has initiated a Phase 1 clinical trial for AT-587, an oral antiviral candidate targeting hepatitis E virus (HEV) infection. The study will assess safety, tolerability, and pharmacokinetics in healthy volunteers using a randomized, double-blind, placebo-controlled design. The trial includes single and multiple ascending dose components, with a food-effect assessment.
Atea Pharmaceuticals, Inc. has completed patient enrollment in its C-FORWARD Phase 3 trial, evaluating the bemnifosbuvir and ruzasvir regimen for HCV. The study enrolled over 880 patients across 17 countries, with topline results anticipated by year-end 2026.
